Leisure, U.S. 206.82% in 5 years Uranium -73% in 2 years Equity, Australia 6.44% in 16 days Thailand 23.78% in 10 months Cotton -25.17% in 7 months Philippines 18.58% in 10 months Construction, U.S. -14.09% in 9 months Global sectors, Health care 31.63% in 3 years Insurance 58.98% in 3 years Rare Earth -82.07% in 3 years Copper Mining -77.44% in 4 years Eastern Europe -66.27% in 4 years Energy, Natural Gas, Commodity -52.27% in 4 months
Latest Strongest Trends:

drug cell human

Industries: Biotechnology,Medical Instruments & Supplies,Drug Manufacturers - Other

No trends starting in last two trading hours.

Description: drug cell human ublituximab GPCRs Phenoxodiol drugs pre-clinical discovery proprietary activity Pracinostat orphan receptors intellectual compounds GPCR Novogen pharmaceutical proteins agents repurchase CLL death disorders signaling Cadus Vulcan lead Protein-coupled function GECS postoperative rituximab exclusive

Top Terms: drug cell human ublituximab GPCRs Phenoxodiol drugs

Trending Motif Instruments Open in screener...

Trend will be:

Continued - 0%No opinion - 100%Reversed - 0%

Horizon
Type

Health Care

Symbol Name Type Description
MEIP MEI Pharma, Inc. Stock MEI Pharma, Inc., formerly Marshall Edwards, Inc., is a development-stage oncology company. The Company is engaged in the development of drugs for the treatment of cancer. The Company focuses on the clinical development of therapeutics targeting cancer metabolism. The Company is a wholly owned subsidiary of Novogen Limited (Novogen). As of September 26, 2011, Novogen owned approximately 51.5% interests in the Company. The Company's has two geographic segments: the United States and Australia. The Company has two clinical product development programs, which include NADH Oxidase Inhibitors and Mitochondrial Inhibitors. NADH Oxidase Inhibitors includes Phenoxodiol and ME-143. Mitochondrial Inhibitors includes NV-128 and ME-344. Marshall Edwards Pty Ltd. is a wholly owned subsidiary of the Company. In February 2013, Novogen Limited completed its exchanged offer through which it was to split off its 63.5% interest in the Company.
MEIP

Relevant?

OMER Omeros Corporation Stock Omeros Corporation operates as a biopharmaceutical company focused on the discovery, development and commercialization of products focused on inflammation and disorders of the central nervous system. The Company develops pharmaceutical and therapeutic approaches to the management of surgical pain and inflammation, vasospasm, smooth muscle spasm, vascular restenosis and implantable surgical devices. Omeros develops products that are delivered directly to the site of tissue injury, preemptively inhibiting inflammation, pain and other problems associated with medical and surgical procedures.
OMER

Relevant?

Capital Goods

Symbol name category description
PKI PerkinElmer, Inc. Stock PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. Through the Company’s advanced technologies, solutions, and services, it addresses issues related to health and safety of people and their environment. It operates in two segments: Human Health and Environmental Health. The Company’s Human Health segment concentrates on developing diagnostics, tools and applications to help detect diseases earlier and accelerate the discovery and development of critical new therapies. The Company’s Environmental Health segment provides technologies and applications to facilitate the creation of safer food and consumer products, secure surroundings and energy resources.
PKI

Relevant?

Health Care

Symbol name category description
TGTX TG Therapeutics, Inc. Stock TG Therapeutics, Inc., formerly Manhattan Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. As of September 13, 2012, the Company was developing two therapies targeting hematological malignancies. TGTX-1101 (ublituximab) is a third generation monoclonal antibody that targets a epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available phosphatidylinositol 3-kinases (PI3K) delta inhibitor. The Company’s product portfolio also includes AST-726. As of December 31, 2011, it owned 13% interest in the H Pharmaceuticals K/S (Hedrin JV).
TGTX

Relevant?

Trending Motif News

 

2014-10-23 16:50:32

PerkinElmer Board Declares Quarterly Dividend

2014-10-23 16:05:00

PerkinElmer Board Declares Quarterly Dividend

2014-10-23 15:10:02

Omeros Falls as Enrollment for OMS824 Study is Suspended

2014-10-22 17:45:43

PerkinElmer Launches Mantra™ Quantitative Pathology Imaging System for Cancer Immunology Research

2014-10-22 06:52:48

Omeros (OMER) Crumbles: Stock Tanks by 12.3%

2014-10-21 08:23:09

Omeros suspends mid-stage trial of Huntington_s drug, shares fall

2014-10-21 08:06:00

Omeros Provides Update on PDE10 Inhibitor Program

2014-10-21 07:03:00

7:03 am Omeros provides update on PDE10 inhibitor program; enrollment in Huntington_s Trial suspended pending further assessment of preclinical data

2014-10-21 07:00:00

Omeros Provides Update on PDE10 Inhibitor Program

2014-10-14 03:09:23

MEI Pharma (MEIP) Soars: Stock Adds 5.5% in Session

2014-10-08 18:03:13

Nasdaq stocks posting largest percentage decreases

2014-10-08 18:03:12

Nasdaq stocks posting largest percentage increases

2014-10-07 07:00:21

OMEROS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement

2014-10-03 16:05:00

PerkinElmer to Hold Earnings Call on Thursday, October 30, 2014

2014-09-29 16:46:30

OMEROS CORP Files SEC form 8-K, Material Modification to Rights of Security Holders, Financial Statements and Exhibit

2014-09-23 16:52:16

TG THERAPEUTICS, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement

2014-09-23 08:01:54

TG THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement

2014-09-23 07:30:00

TG Therapeutics Announces Exercise of License Option for Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202

2014-09-18 09:00:00

MEI Pharma To Present At BioCentury_s NewsMakers Conference

2014-09-18 08:15:39

TG Therapeutics (TGTX) in Focus: Stock Gains 16.1%

2014-09-15 07:14:41

TG THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2014-09-15 07:00:00

TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for Its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination With Imbruvica(R) (ibrutinib) for Patients With Previously Treated Chronic Lymph

2014-09-15 06:57:21

Increased Earnings Estimates Seen for Omeros Corporation (OMER): Can It Move Higher?

2014-09-13 13:04:11

MEI PHARMA, INC. Financials

2014-09-12 16:05:44

PERKINELMER INC Files SEC form 8-K, Change in Directors or Principal Officers

2014-09-12 12:20:00

5 Breakout Stocks Under $10 Set to Soar

2014-09-09 09:15:55

MEI PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

2014-09-09 09:00:00

MEI Pharma Reports Fiscal Year 2014 Results

2014-09-09 08:01:21

MEI PHARMA, INC. Files SEC form 10-K, Annual Report

2014-09-08 16:27:57

UPDATE -- TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference

2014-09-08 09:25:00

TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference

2014-09-04 06:41:26

TG Therapeutics (TGTX) Worth Watching: Stock Up 9.1%

2014-09-02 09:06:58

MEI PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2014-09-02 08:30:00

MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome

2014-09-02 03:00:00

Louis Culot Appointed as BioData_s CEO

2014-08-29 02:16:28

Two Portfolios. Pick One.

2014-08-19 13:04:30

OMEROS CORP Financials

2014-08-18 16:10:03

Ligand Up on Multi-Program Captisol Deal with Avion Pharma

2014-08-15 07:30:00

TG Therapeutics Announces Novel _Chemo-free_ Triple Therapy Combination Clinical Study for Patients With Chronic Lymphocytic Leukemia and Other B-cell Malignancies

2014-08-12 13:04:16

PERKINELMER INC Financials

2014-08-12 07:39:48

Coverage initiated on PerkinElmer by Stifel

2014-08-11 16:10:42

OMEROS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

2014-08-11 16:03:53

OMEROS CORP Files SEC form 10-Q, Quarterly Report

2014-08-11 16:03:00

Omeros Corporation Reports Second Quarter 2014 Financial Results

2014-08-08 07:12:21

Falling Earnings Estimates Signal Weakness Ahead for TG Therapeutics (TGTX)

2014-08-08 07:00:00

Omeros to Present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference

2014-08-06 09:00:00

MEI Pharma To Present At Wedbush PacGrow Life Sciences And Canaccord Genuity Growth Conferences

2014-08-05 13:15:54

PERKINELMER INC Files SEC form 10-Q, Quarterly Report

2014-08-01 12:16:00

Dr. Phillip P. Chan, the CEO and President of CytoSorbents Corporation (CTSO), Interviews with The Wall Street Transcript

2014-08-01 09:54:54

PerkinElmer Q2 Earnings Meet but Revenues Miss Estimates

2014-07-31 17:21:09

PerkinElmer profit meets Wall Street view; not seeking inversion

2014-07-31 17:00:00

PerkinElmer Inc Earnings Call scheduled for 5:00 pm ET today

2014-07-31 16:34:56

PERKINELMER INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

2014-07-31 16:26:45

PerkinElmer 2nd quarter profit meets Wall Street view

2014-07-31 16:05:00

PerkinElmer Announces Financial Results for the Second Quarter of 2014

2014-07-31 13:04:13

TG THERAPEUTICS, INC. Financials

2014-07-31 07:07:05

Q2 2014 PerkinElmer Earnings Release - After Market Close

2014-07-24 16:57:00

PerkinElmer Board Declares Quarterly Dividend

2014-07-24 16:37:27

TG THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report

2014-07-22 13:24:15

Why TG Therapeutics, Inc. Stock Was Whipsawed

2014-07-21 17:22:03

TG THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights

2014-07-21 16:05:00

TG Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Business Update

2014-07-21 16:05:00

TG Therapeutics_ Novel Combination of TG-1101 (Ublituximab) and TGR-1202 Demonstrates Compelling Early Activity and Safety Profile in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) and Aggressive Lymphomas

2014-07-17 11:36:00

Danaher Q2 Earnings, Guidance Disappoint Wall Street

2014-07-11 07:00:00

3 Biotech Stocks Under $10 to Trade for Breakouts

2014-07-09 07:00:19

Omeros Slumps: OMER Falls 10.4% in Session

2014-07-07 16:23:00

PerkinElmer to Hold Earnings Call on Thursday, July 31, 2014

2014-07-07 07:48:09

Omeros (OMER) Enters Overbought Territory

2014-07-06 15:00:10

3 Stocks That Soared Stupendously This Week

2014-07-03 08:11:33

TG Therapeutics (TGTX) in Focus: Stock Moves 10.4% Higher

2014-07-02 08:18:00

4 Biotech Stocks Under $10 to Watch for Breakout Trades

2014-06-26 06:37:55

Omeros Corporation (OMER) Gains: Stock Up 8.92%

2014-06-25 14:47:55

Qualifying Speculation In Omeros Corporation

2014-06-22 11:49:28

PerkinElmer: 6 Different Insiders Have Sold Shares This Month

2014-06-12 09:21:17

Omeros (OMER) Enters Overbought Territory

2014-06-10 16:40:15

PerkinElmer Launches New Air Monitoring Service

2014-06-10 08:30:00

MEI Pharma Reports High Response Rates In Phase II Study Of Pracinostat In Front Line Acute Myeloid Leukemia

2014-06-09 18:53:00

A Few Medical Research Stocks Break Out, Others Basing

2014-06-09 09:00:00

MEI Pharma To Present At Wells Fargo Healthcare Conference

2014-06-06 13:15:57

2 Small-Cap Biotechs for Your Watchlist

2014-06-03 17:40:04

Omeros_ Omidria Gets FDA Nod

2014-06-02 12:20:31

Midday movers: Allergan, Valeant, US Steel & more

2014-06-02 09:10:14

Monday’s Top Biotech Stories: Ariad, Omeros, NPS Pharmaceuticals, and Shire

2014-06-02 08:37:11

Moving Average Crossover Alert: MEI Pharma (MEIP)

2014-06-02 07:15:24

FDA approves Omeros eye drug

2014-06-02 07:06:18

OMEROS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2014-06-02 07:00:00

Omeros Receives FDA Approval of Omidria™ for Use in Cataract and Other Intraocular Lens Replacement Procedures

2014-05-08 09:00:00

MEI Pharma to Present at Bank of America Merrill Lynch and UBS Healthcare Conferences

2014-05-08 08:31:34

MEI PHARMA, INC. Files SEC form 10-Q, Quarterly Report

2014-05-05 09:00:00

MEI Pharma Initiates Clinical Study Of Mitochondrial Inhibitor Drug Candidate ME-344 In Small Cell Lung And Ovarian Cancers

2014-05-01 10:52:00

A Wall Street Transcript Interview with David Nierengarten, Ph.D., an Analyst at Wedbush Securities Covering the Biotechnology, Biopharmaceuticals and Biodefense Sector: Targeted Genetic and Cell Therapies Stand Out in Biotechnology

2014-04-08 09:24:41

MEI PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits

 

Comments

You have to sign in to write a comment.

There is no comments yet.
facebook